MUMBAI, India, Oct. 5 -- Intellectual Property India has published a patent application (202611102067 A) filed by Mukul Kumar; Vijay Ojha; Dr. Nookesh Kotipalli; Dr Pasupuleti Sreenivasa Rao; Prof. Dr. Maninder Pal Singh; Nitish Nirala; Himanshu Bansode; Monali Moreshwar Sawarbande; Lalita Singh; and Arti Chandel on August 24, 2026, for Pharmacokinetic-Enhanced Phytosomal Nanocarrier Of A Polyherbal Antidiabetic Composition For Sustained Release And Improved Oral Bioavailability.
Inventors include Mukul Kumar; Vijay Ojha; Dr. Nookesh Kotipalli; Dr Pasupuleti Sreenivasa Rao; Prof. Dr. Maninder Pal Singh; Nitish Nirala; Himanshu Bansode; Monali Moreshwar Sawarbande; Lalita Singh; and Arti Chandel.
The application for the patent was published on October 02, 2026, under issue no. 40/2026.
Abstract: The present invention relates to a pharmacokinetic-enhanced phytosomal nanocarrier comprising a standardized polyherbal antidiabetic composition for sustained release and improved oral bioavailability. The invention comprises at least two standardized botanical extracts containing antidiabetic phytoconstituents, wherein the bioactive constituents are associated with one or more phospholipids to form a phytosomal complex and subsequently processed into nanoscale particles. The developed nanocarrier demonstrated improved physicochemical characteristics, nanoscale particle size, satisfactory size distribution, enhanced association of marker phytoconstituents and controlled release characteristics. Physicochemical characterization using FTIR, DSC and XRD supported formation of the phytosomal system and modification of the physicochemical state of the incorporated constituents. The optimized formulation demonstrated improved gastrointestinal stability and intestinal permeation compared with the corresponding conventional polyherbal composition. Pharmacokinetic evaluation demonstrated enhancement of systemic exposure, as evidenced by modification of Cmax, AUC, Tmax, half-life and mean residence time of selected marker phytoconstituents. The formulation further demonstrated improved pharmacodynamic antidiabetic activity, including regulation of blood glucose and associated metabolic parameters. The invention therefore provides a standardized nanoscale phytosomal platform capable of improving oral bioavailability and sustaining systemic delivery of multiple herbal bioactive constituents for management of diabetes and associated metabolic dysfunctions.
Disclaimer: Curated by HT Syndication.
